Azacitidine - EVER Pharma Italia

Dosage Form	Powder for suspension for injection
Strength	25 mg/ml
Strength per Unit	100 mg, 150 mg
ATC Code	L01BC07
Drug Class	Antineoplastic agents, pyrimidine analogues
Indication	Azacitidine is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: − intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS), − chronic myelomonocytic leukaemia (CMML) with 10–29 % marrow blasts without myeloproliferative disorder, − acute myeloid leukaemia (AML) with 20–30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification, − AML with > 30 % marrow blasts according to the WHO classification.

Azacitidine EVER Pharma is a prescription medication. Information for healthcare professionalsationen nur für medizinisches Fachpersonal.
See the Summary of Product Characteristics for full information about the medication.